SAN FRANCISCO--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today reported phase 1 data from a dose-escalation study of XL019 in patients with myelofibrosis (MF). XL019 is a potent small molecule inhibitor of JAK2, a protein kinase that is mutationally-activated in approximately 50% of patients in MF. Neil Shah, MD, Ph.D., Assistant Professor in the Division of Hematology/Oncology at the University of California, San Francisco, reported the data in an oral presentation (Abstract #98) at the 50th Annual Meeting of the American Society of Hematology, which is being held Dec. 6-8, 2008 in San Francisco.
